Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Clinical trial NCT03581487 · COMPLETED

Trial details

NCT number: NCT03581487
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Recurrent Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8

Start date: 2019-04-01
Primary completion: 2025-10-30
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.